EEG Biofeedback to Improve Memory in Adults With Dementia (QMFFTD)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT01168466|
Recruitment Status : Completed
First Posted : July 23, 2010
Last Update Posted : April 2, 2018
|Condition or disease||Intervention/treatment||Phase|
|Dementia||Behavioral: QEEG-based Neurofeedback Training||Not Applicable|
Show Detailed Description
|Study Type :||Interventional (Clinical Trial)|
|Actual Enrollment :||37 participants|
|Intervention Model:||Parallel Assignment|
|Masking:||Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)|
|Official Title:||Pilot Study of EEG and Cerebral Blood Flow Biofeedback Training in Remediating Cognitive and Behavioral Deficits in Adults With a Dementing Illness.|
|Study Start Date :||June 2007|
|Actual Primary Completion Date :||June 2008|
|Actual Study Completion Date :||June 2008|
No Intervention: Neurofeedback
Waitlist control group.
Experimental: QEEG-based Neurofeedback Training
A randomly selected half of participants waits 15 weeks for the other half to complete treatment, and are then reassessed, serving as controls. They then receive the same treatment as the experimental group.
Behavioral: QEEG-based Neurofeedback Training
EEG amplitude is measured and visual and auditory rewards are given when amplitude at specific locations is modified to meet preset threshholds.
Other Name: Neurofeedback
- Delis-Kaplan Executive Function System, Behavior Rating Inventory of Executive Function- Adult Version, Integrated Visual and Auditory Continuous Performance Test, Symptom Checklist 90R [ Time Frame: Within two weeks of last session ]
- EEG amplitude [ Time Frame: within two weeks of last session ]decreased slow wave amplitudes from 1-4hz
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01168466
|United States, Pennsylvania|
|Lafayette Hill, Pennsylvania, United States, 19444-1800|
|Principal Investigator:||Marvin H Berman, Ph.D.||Quietmind Foundation|
|Study Director:||Jon Frederick, Ph.D.||Quietmind Foundation|